• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CoCo Therapeutics created to develop new treatments for Alzheimer’s disease

CoCo Therapeutics created to develop new treatments for Alzheimer’s disease

March 8, 2013
CenterWatch Staff

King’s College London, The Wellcome Trust and Advent Venture Partners have announced the formation of a new U.K. biotechnology company, CoCo Therapeutics, to progress the research of Professor Jonathan Corcoran into the development of new treatments for Alzheimer’s disease.

The company will build on the success of research funded through the Wellcome Trust’s Seeding Drug Discovery initiative investigating the role of the retinoic acid receptor, RAR-alpha, and molecules that act on it in Alzheimer’s disease.

The neuroscience drug discovery unit at King’s, led by Professor Corcoran, has been optimizing compounds for treatment of CNS disorders since 2008. The group previously has shown that molecules that act on RAR-alpha can affect multiple parts of the Alzheimer’s pathway and have the potential to produce an effective therapy that would otherwise need several points of intervention from different drugs. CoCo Therapeutics now will take forward the lead compound into late-stage preclinical studies and clinical trials.

Funding has been provided by Advent Venture Partners, one of Europe's venture capital investors in technology and life sciences businesses. Dr. Raj Parekh, general partner at Advent, will be the founding chairman of the new company.

 “Our research has shown early promise in this area and this partnership will enable us to progress the work further,” said Corcoran. “This is an exciting step forward in the search for effective Alzheimer's disease treatments.”

CoCo Therapeutics also has named Dr. Steve Butcher chief operating officer. Dr. Butcher was a founder and scientific director of the Fujisawa Institute of Neuroscience before holding management positions at Pharmacia. More recently, he held executive positions in biotechnology companies including BioImage and TopoTarget.

Enter Content Here

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing